Enveric Biosciences (NASDAQ:ENVB – Get Free Report) is expected to be releasing its earnings data before the market opens on Monday, March 24th. Analysts expect Enveric Biosciences to post earnings of ($6.00) per share for the quarter.
Enveric Biosciences Trading Up 0.6 %
NASDAQ:ENVB opened at $1.74 on Friday. Enveric Biosciences has a 1 year low of $1.13 and a 1 year high of $18.00. The stock has a market cap of $1.18 million, a price-to-earnings ratio of -0.05 and a beta of 0.47. The stock has a 50-day moving average price of $2.65 and a two-hundred day moving average price of $5.06.
Analyst Upgrades and Downgrades
Separately, HC Wainwright reaffirmed a “buy” rating and set a $10.00 price objective on shares of Enveric Biosciences in a research report on Thursday, March 6th.
Enveric Biosciences Company Profile
Enveric Biosciences, Inc, a biotechnology company, engages in the development of small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders. Its lead product candidates are EB-002, an active metabolite of psilocybin, which is in preclinical development stage for the treatment of anxiety disorders; and EB-003 that is in preclinical development stage for the treatment mental health.
Read More
- Five stocks we like better than Enveric Biosciences
- How to Capture the Benefits of Dividend Increases
- FedEx Delivers Another Crushing Blow to Its Stock Price
- What is the Shanghai Stock Exchange Composite Index?
- Analysts Stay Bullish on Rocket Lab as Signs of a Bottom Emerge
- When to Sell a Stock for Profit or Loss
- Micron Stock Will Retest All-Time Highs This Year
Receive News & Ratings for Enveric Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enveric Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
